Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
08 avr. 2024 08h30 HE
|
Nuvectis Pharma, Inc.
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells...
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
19 mars 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Present at the 36th Annual Roth Conference
15 mars 2024 08h00 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
14 mars 2024 09h00 HE
|
Nuvectis Pharma, Inc.
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a...
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
05 mars 2024 08h00 HE
|
Nuvectis Pharma, Inc.
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDANXP800...
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09 févr. 2024 08h32 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09 févr. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
18 déc. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by...
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
08 nov. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid...